ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000511

NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies

Identifieur interne : 000511 ( PascalFrancis/Corpus ); précédent : 000510; suivant : 000512

NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies

Auteurs : Ali Samii ; Mahyar Etminan ; Matthew O. Wiens ; Siavash Jafari

Source :

Drugs & aging [ 1170-229X ] ; 2009.

RBID : Pascal:09-0427296

Descripteurs français

Pascal (Inist)
- Antiinflammatoire non stéroïde, Facteur risque, Maladie de Parkinson, Revue systématique, Article synthèse, Métaanalyse, Personne âgée, Ibuprofène, Acide acétylsalicylique, Analgésique, Antipyrétique, Inhibiteur thromboagrégation, Risque relatif.

English descriptors

KwdEn :
- Acetylsalicylic acid, Analgesic, Antiplatelet agent, Antipyretic, Elderly, Ibuprofen, Metaanalysis, Non steroidal antiinflammatory agent, Parkinson disease, Relative risk, Review, Risk factor, Systematic review.

Abstract

Background: Several studies have suggested that NSAID use may modify the risk of developing Parkinson's disease (PD). Objective: Our aim was to conduct a meta-analysis of observational studies evaluating NSAID use and the risk of PD. Methods: We systematically searched MEDLINE (1966-November 2008), EMBASE (1980-November 2008) and other databases. Data from 11 studies were included in the meta-analysis. We used the random effects model to calculate risk ratios (relative risks) and their corresponding 95% confidence intervals (CIs). Results: The pooled risk ratio of PD with NSAID use was 0.95 (95% CI 0.80, 1.12). The pooled risk ratio of PD with high-dose or long-duration NSAID use was 0.91 (95% CI 0.78, 1.05). The pooled risk ratio of PD for aspirin (acetylsalicylic acid) users was 1.08 (95% CI 0.93, 1.26). The pooled risk ratio of PD among ibuprofen users was 0.76 (95% CI 0.65, 0.89). The pooled risk ratio of PD in men using NSAIDs was 0.79 (95% CI 0.69, 0.92), and in women using NSAIDs, it was 0.72 (95% CI 0.45, 1.15). Conclusions: NSAIDs as a class do not seem to modify the risk of PD. However, ibuprofen may have a slight protective effect in lowering the risk of PD. Although the risk ratios of PD in male and female NSAID users were similar, the 95% CI for men was suggestive of a slight risk reduction.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1170-229X`
A03		`1`		`@0 Drugs aging`
A05				`@2 26`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies`
A11	`01`	`1`		`@1 SAMII (Ali)`
A11	`02`	`1`		`@1 ETMINAN (Mahyar)`
A11	`03`	`1`		`@1 WIENS (Matthew O.)`
A11	`04`	`1`		`@1 JAFARI (Siavash)`
A14	`01`			`@1 Department of Neurology, University of Washington, and the Seattle VA Parkinson Disease Research Education and Clinical Center @2 Seattle, Washington @3 USA @Z 1 aut.`
A14	`02`			`@1 Centre for Clinical Epidemiology and Evaluation, Department of Medicine, Faculty of Medicine, University of British Columbia @2 Vancouver, British Columbia @3 CAN @Z 2 aut.`
A14	`03`			`@1 Faculty of Pharmaceutical Sciences, University of British Columbia @2 Vancouver, British Columbia @3 CAN @Z 3 aut.`
A14	`04`			`@1 Chilliwack General Hospital @2 Chilliwack, British Columbia @3 CAN @Z 3 aut.`
A14	`05`			`@1 School of Population and Public Health, University of British Columbia @2 Vancouver, British Columbia @3 CAN @Z 4 aut.`
A20				`@1 769-779`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26115 @5 354000170024200040`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 28 ref.`
A47	`01`	`1`		`@0 09-0427296`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Drugs & aging`
A66	`01`			`@0 NZL`
C01	`01`		`ENG`	@0 Background: Several studies have suggested that NSAID use may modify the risk of developing Parkinson's disease (PD). Objective: Our aim was to conduct a meta-analysis of observational studies evaluating NSAID use and the risk of PD. Methods: We systematically searched MEDLINE (1966-November 2008), EMBASE (1980-November 2008) and other databases. Data from 11 studies were included in the meta-analysis. We used the random effects model to calculate risk ratios (relative risks) and their corresponding 95% confidence intervals (CIs). Results: The pooled risk ratio of PD with NSAID use was 0.95 (95% CI 0.80, 1.12). The pooled risk ratio of PD with high-dose or long-duration NSAID use was 0.91 (95% CI 0.78, 1.05). The pooled risk ratio of PD for aspirin (acetylsalicylic acid) users was 1.08 (95% CI 0.93, 1.26). The pooled risk ratio of PD among ibuprofen users was 0.76 (95% CI 0.65, 0.89). The pooled risk ratio of PD in men using NSAIDs was 0.79 (95% CI 0.69, 0.92), and in women using NSAIDs, it was 0.72 (95% CI 0.45, 1.15). Conclusions: NSAIDs as a class do not seem to modify the risk of PD. However, ibuprofen may have a slight protective effect in lowering the risk of PD. Although the risk ratios of PD in male and female NSAID users were similar, the 95% CI for men was suggestive of a slight risk reduction.
C02	`01`	`X`		`@0 002B02B05`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A01`
C03	`01`	`X`	`FRE`	`@0 Antiinflammatoire non stéroïde @5 01`
C03	`01`	`X`	`ENG`	`@0 Non steroidal antiinflammatory agent @5 01`
C03	`01`	`X`	`SPA`	`@0 Antiinflamatorio no esteroide @5 01`
C03	`02`	`X`	`FRE`	`@0 Facteur risque @5 02`
C03	`02`	`X`	`ENG`	`@0 Risk factor @5 02`
C03	`02`	`X`	`SPA`	`@0 Factor riesgo @5 02`
C03	`03`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Revue systématique @2 FM @5 04`
C03	`04`	`X`	`ENG`	`@0 Systematic review @2 FM @5 04`
C03	`04`	`X`	`SPA`	`@0 Revisión sistemática @2 FM @5 04`
C03	`05`	`X`	`FRE`	`@0 Article synthèse @5 05`
C03	`05`	`X`	`ENG`	`@0 Review @5 05`
C03	`05`	`X`	`SPA`	`@0 Artículo síntesis @5 05`
C03	`06`	`X`	`FRE`	`@0 Métaanalyse @5 06`
C03	`06`	`X`	`ENG`	`@0 Metaanalysis @5 06`
C03	`06`	`X`	`SPA`	`@0 Meta-análisis @5 06`
C03	`07`	`X`	`FRE`	`@0 Personne âgée @5 07`
C03	`07`	`X`	`ENG`	`@0 Elderly @5 07`
C03	`07`	`X`	`SPA`	`@0 Anciano @5 07`
C03	`08`	`X`	`FRE`	`@0 Ibuprofène @2 NK @2 FR @5 08`
C03	`08`	`X`	`ENG`	`@0 Ibuprofen @2 NK @2 FR @5 08`
C03	`08`	`X`	`SPA`	`@0 Ibuprofeno @2 NK @2 FR @5 08`
C03	`09`	`X`	`FRE`	`@0 Acide acétylsalicylique @2 NK @2 FR @5 09`
C03	`09`	`X`	`ENG`	`@0 Acetylsalicylic acid @2 NK @2 FR @5 09`
C03	`09`	`X`	`SPA`	`@0 Acetilsalicilico ácido @2 NK @2 FR @5 09`
C03	`10`	`X`	`FRE`	`@0 Analgésique @5 24`
C03	`10`	`X`	`ENG`	`@0 Analgesic @5 24`
C03	`10`	`X`	`SPA`	`@0 Analgésico @5 24`
C03	`11`	`X`	`FRE`	`@0 Antipyrétique @5 25`
C03	`11`	`X`	`ENG`	`@0 Antipyretic @5 25`
C03	`11`	`X`	`SPA`	`@0 Antipirético @5 25`
C03	`12`	`X`	`FRE`	`@0 Inhibiteur thromboagrégation @5 26`
C03	`12`	`X`	`ENG`	`@0 Antiplatelet agent @5 26`
C03	`12`	`X`	`SPA`	`@0 Inhibidor tromboagregación @5 26`
C03	`13`	`X`	`FRE`	`@0 Risque relatif @4 CD @5 96`
C03	`13`	`X`	`ENG`	`@0 Relative risk @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Maladie dégénérative @5 37`
C07	`02`	`X`	`ENG`	`@0 Degenerative disease @5 37`
C07	`02`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 37`
C07	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 38`
C07	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 38`
C07	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 39`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 40`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`06`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 41`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
C07	`07`	`X`	`FRE`	`@0 Dérivé de l'acide arylpropionique @5 42`
C07	`07`	`X`	`ENG`	`@0 Arylpropionic acid derivatives @5 42`
C07	`07`	`X`	`SPA`	`@0 Arilpropionico ácido derivado @5 42`
C07	`08`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 43`
C07	`08`	`X`	`ENG`	`@0 Enzyme inhibitor @5 43`
C07	`08`	`X`	`SPA`	`@0 Inhibidor enzima @5 43`
C07	`09`	`X`	`FRE`	`@0 Prostaglandin-endoperoxide synthase @2 FE @5 44`
C07	`09`	`X`	`ENG`	`@0 Prostaglandin-endoperoxide synthase @2 FE @5 44`
C07	`09`	`X`	`SPA`	`@0 Prostaglandin-endoperoxide synthase @2 FE @5 44`
C07	`10`	`X`	`FRE`	`@0 Oxidoreductases @2 FE`
C07	`10`	`X`	`ENG`	`@0 Oxidoreductases @2 FE`
C07	`10`	`X`	`SPA`	`@0 Oxidoreductases @2 FE`
C07	`11`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`11`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`11`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`12`	`X`	`FRE`	`@0 Salicylés @5 45`
C07	`12`	`X`	`ENG`	`@0 Salicylates @5 45`
C07	`12`	`X`	`SPA`	`@0 Salicilatos @5 45`
N21				`@1 306`

Format Inist (serveur)

NO :	PASCAL 09-0427296 INIST
ET :	NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies
AU :	SAMII (Ali); ETMINAN (Mahyar); WIENS (Matthew O.); JAFARI (Siavash)
AF :	Department of Neurology, University of Washington, and the Seattle VA Parkinson Disease Research Education and Clinical Center/Seattle, Washington/Etats-Unis (1 aut.); Centre for Clinical Epidemiology and Evaluation, Department of Medicine, Faculty of Medicine, University of British Columbia/Vancouver, British Columbia/Canada (2 aut.); Faculty of Pharmaceutical Sciences, University of British Columbia/Vancouver, British Columbia/Canada (3 aut.); Chilliwack General Hospital/Chilliwack, British Columbia/Canada (3 aut.); School of Population and Public Health, University of British Columbia/Vancouver, British Columbia/Canada (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Drugs & aging; ISSN 1170-229X; Nouvelle-Zélande; Da. 2009; Vol. 26; No. 9; Pp. 769-779; Bibl. 28 ref.
LA :	Anglais
EA :	Background: Several studies have suggested that NSAID use may modify the risk of developing Parkinson's disease (PD). Objective: Our aim was to conduct a meta-analysis of observational studies evaluating NSAID use and the risk of PD. Methods: We systematically searched MEDLINE (1966-November 2008), EMBASE (1980-November 2008) and other databases. Data from 11 studies were included in the meta-analysis. We used the random effects model to calculate risk ratios (relative risks) and their corresponding 95% confidence intervals (CIs). Results: The pooled risk ratio of PD with NSAID use was 0.95 (95% CI 0.80, 1.12). The pooled risk ratio of PD with high-dose or long-duration NSAID use was 0.91 (95% CI 0.78, 1.05). The pooled risk ratio of PD for aspirin (acetylsalicylic acid) users was 1.08 (95% CI 0.93, 1.26). The pooled risk ratio of PD among ibuprofen users was 0.76 (95% CI 0.65, 0.89). The pooled risk ratio of PD in men using NSAIDs was 0.79 (95% CI 0.69, 0.92), and in women using NSAIDs, it was 0.72 (95% CI 0.45, 1.15). Conclusions: NSAIDs as a class do not seem to modify the risk of PD. However, ibuprofen may have a slight protective effect in lowering the risk of PD. Although the risk ratios of PD in male and female NSAID users were similar, the 95% CI for men was suggestive of a slight risk reduction.
CC :	002B02B05; 002B17G; 002B17A01
FD :	Antiinflammatoire non stéroïde; Facteur risque; Maladie de Parkinson; Revue systématique; Article synthèse; Métaanalyse; Personne âgée; Ibuprofène; Acide acétylsalicylique; Analgésique; Antipyrétique; Inhibiteur thromboagrégation; Risque relatif
FG :	Homme; Maladie dégénérative; Pathologie du système nerveux; Pathologie de l'encéphale; Syndrome extrapyramidal; Pathologie du système nerveux central; Dérivé de l'acide arylpropionique; Inhibiteur enzyme; Prostaglandin-endoperoxide synthase; Oxidoreductases; Enzyme; Salicylés
ED :	Non steroidal antiinflammatory agent; Risk factor; Parkinson disease; Systematic review; Review; Metaanalysis; Elderly; Ibuprofen; Acetylsalicylic acid; Analgesic; Antipyretic; Antiplatelet agent; Relative risk
EG :	Human; Degenerative disease; Nervous system diseases; Cerebral disorder; Extrapyramidal syndrome; Central nervous system disease; Arylpropionic acid derivatives; Enzyme inhibitor; Prostaglandin-endoperoxide synthase; Oxidoreductases; Enzyme; Salicylates
SD :	Antiinflamatorio no esteroide; Factor riesgo; Parkinson enfermedad; Revisión sistemática; Artículo síntesis; Meta-análisis; Anciano; Ibuprofeno; Acetilsalicilico ácido; Analgésico; Antipirético; Inhibidor tromboagregación
LO :	INIST-26115.354000170024200040
ID :	09-0427296

Links to Exploration step

Pascal:09-0427296

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies</title>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Washington, and the Seattle VA Parkinson Disease Research Education and Clinical Center</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<affiliation><inist:fA14 i1="02"><s1>Centre for Clinical Epidemiology and Evaluation, Department of Medicine, Faculty of Medicine, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wiens, Matthew O" sort="Wiens, Matthew O" uniqKey="Wiens M" first="Matthew O." last="Wiens">Matthew O. Wiens</name>
<affiliation><inist:fA14 i1="03"><s1>Faculty of Pharmaceutical Sciences, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Chilliwack General Hospital</s1>
<s2>Chilliwack, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jafari, Siavash" sort="Jafari, Siavash" uniqKey="Jafari S" first="Siavash" last="Jafari">Siavash Jafari</name>
<affiliation><inist:fA14 i1="05"><s1>School of Population and Public Health, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0427296</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0427296 INIST</idno>
<idno type="RBID">Pascal:09-0427296</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000511</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies</title>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Washington, and the Seattle VA Parkinson Disease Research Education and Clinical Center</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<affiliation><inist:fA14 i1="02"><s1>Centre for Clinical Epidemiology and Evaluation, Department of Medicine, Faculty of Medicine, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wiens, Matthew O" sort="Wiens, Matthew O" uniqKey="Wiens M" first="Matthew O." last="Wiens">Matthew O. Wiens</name>
<affiliation><inist:fA14 i1="03"><s1>Faculty of Pharmaceutical Sciences, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Chilliwack General Hospital</s1>
<s2>Chilliwack, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jafari, Siavash" sort="Jafari, Siavash" uniqKey="Jafari S" first="Siavash" last="Jafari">Siavash Jafari</name>
<affiliation><inist:fA14 i1="05"><s1>School of Population and Public Health, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Drugs & aging</title>
<title level="j" type="abbreviated">Drugs aging</title>
<idno type="ISSN">1170-229X</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Drugs & aging</title>
<title level="j" type="abbreviated">Drugs aging</title>
<idno type="ISSN">1170-229X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylsalicylic acid</term>
<term>Analgesic</term>
<term>Antiplatelet agent</term>
<term>Antipyretic</term>
<term>Elderly</term>
<term>Ibuprofen</term>
<term>Metaanalysis</term>
<term>Non steroidal antiinflammatory agent</term>
<term>Parkinson disease</term>
<term>Relative risk</term>
<term>Review</term>
<term>Risk factor</term>
<term>Systematic review</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiinflammatoire non stéroïde</term>
<term>Facteur risque</term>
<term>Maladie de Parkinson</term>
<term>Revue systématique</term>
<term>Article synthèse</term>
<term>Métaanalyse</term>
<term>Personne âgée</term>
<term>Ibuprofène</term>
<term>Acide acétylsalicylique</term>
<term>Analgésique</term>
<term>Antipyrétique</term>
<term>Inhibiteur thromboagrégation</term>
<term>Risque relatif</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Several studies have suggested that NSAID use may modify the risk of developing Parkinson's disease (PD). Objective: Our aim was to conduct a meta-analysis of observational studies evaluating NSAID use and the risk of PD. Methods: We systematically searched MEDLINE (1966-November 2008), EMBASE (1980-November 2008) and other databases. Data from 11 studies were included in the meta-analysis. We used the random effects model to calculate risk ratios (relative risks) and their corresponding 95% confidence intervals (CIs). Results: The pooled risk ratio of PD with NSAID use was 0.95 (95% CI 0.80, 1.12). The pooled risk ratio of PD with high-dose or long-duration NSAID use was 0.91 (95% CI 0.78, 1.05). The pooled risk ratio of PD for aspirin (acetylsalicylic acid) users was 1.08 (95% CI 0.93, 1.26). The pooled risk ratio of PD among ibuprofen users was 0.76 (95% CI 0.65, 0.89). The pooled risk ratio of PD in men using NSAIDs was 0.79 (95% CI 0.69, 0.92), and in women using NSAIDs, it was 0.72 (95% CI 0.45, 1.15). Conclusions: NSAIDs as a class do not seem to modify the risk of PD. However, ibuprofen may have a slight protective effect in lowering the risk of PD. Although the risk ratios of PD in male and female NSAID users were similar, the 95% CI for men was suggestive of a slight risk reduction.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1170-229X</s0>
</fA01>
<fA03 i2="1"><s0>Drugs aging</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SAMII (Ali)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ETMINAN (Mahyar)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>WIENS (Matthew O.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JAFARI (Siavash)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of Washington, and the Seattle VA Parkinson Disease Research Education and Clinical Center</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Centre for Clinical Epidemiology and Evaluation, Department of Medicine, Faculty of Medicine, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Faculty of Pharmaceutical Sciences, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Chilliwack General Hospital</s1>
<s2>Chilliwack, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>School of Population and Public Health, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>769-779</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26115</s2>
<s5>354000170024200040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>28 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0427296</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Drugs & aging</s0>
</fA64>
<fA66 i1="01"><s0>NZL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Several studies have suggested that NSAID use may modify the risk of developing Parkinson's disease (PD). Objective: Our aim was to conduct a meta-analysis of observational studies evaluating NSAID use and the risk of PD. Methods: We systematically searched MEDLINE (1966-November 2008), EMBASE (1980-November 2008) and other databases. Data from 11 studies were included in the meta-analysis. We used the random effects model to calculate risk ratios (relative risks) and their corresponding 95% confidence intervals (CIs). Results: The pooled risk ratio of PD with NSAID use was 0.95 (95% CI 0.80, 1.12). The pooled risk ratio of PD with high-dose or long-duration NSAID use was 0.91 (95% CI 0.78, 1.05). The pooled risk ratio of PD for aspirin (acetylsalicylic acid) users was 1.08 (95% CI 0.93, 1.26). The pooled risk ratio of PD among ibuprofen users was 0.76 (95% CI 0.65, 0.89). The pooled risk ratio of PD in men using NSAIDs was 0.79 (95% CI 0.69, 0.92), and in women using NSAIDs, it was 0.72 (95% CI 0.45, 1.15). Conclusions: NSAIDs as a class do not seem to modify the risk of PD. However, ibuprofen may have a slight protective effect in lowering the risk of PD. Although the risk ratios of PD in male and female NSAID users were similar, the 95% CI for men was suggestive of a slight risk reduction.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Antiinflammatoire non stéroïde</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Non steroidal antiinflammatory agent</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Antiinflamatorio no esteroide</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Revue systématique</s0>
<s2>FM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Systematic review</s0>
<s2>FM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Revisión sistemática</s0>
<s2>FM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Review</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Métaanalyse</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Metaanalysis</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Meta-análisis</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Elderly</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Anciano</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Ibuprofène</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Ibuprofen</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Ibuprofeno</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Acide acétylsalicylique</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Acetylsalicylic acid</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Acetilsalicilico ácido</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Analgésique</s0>
<s5>24</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Analgesic</s0>
<s5>24</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Analgésico</s0>
<s5>24</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Antipyrétique</s0>
<s5>25</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Antipyretic</s0>
<s5>25</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Antipirético</s0>
<s5>25</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Inhibiteur thromboagrégation</s0>
<s5>26</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Antiplatelet agent</s0>
<s5>26</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Inhibidor tromboagregación</s0>
<s5>26</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Risque relatif</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Relative risk</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Dérivé de l'acide arylpropionique</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Arylpropionic acid derivatives</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Arilpropionico ácido derivado</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Prostaglandin-endoperoxide synthase</s0>
<s2>FE</s2>
<s5>44</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Prostaglandin-endoperoxide synthase</s0>
<s2>FE</s2>
<s5>44</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Prostaglandin-endoperoxide synthase</s0>
<s2>FE</s2>
<s5>44</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Salicylés</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Salicylates</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Salicilatos</s0>
<s5>45</s5>
</fC07>
<fN21><s1>306</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 09-0427296 INIST</NO>
<ET>NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies</ET>
<AU>SAMII (Ali); ETMINAN (Mahyar); WIENS (Matthew O.); JAFARI (Siavash)</AU>
<AF>Department of Neurology, University of Washington, and the Seattle VA Parkinson Disease Research Education and Clinical Center/Seattle, Washington/Etats-Unis (1 aut.); Centre for Clinical Epidemiology and Evaluation, Department of Medicine, Faculty of Medicine, University of British Columbia/Vancouver, British Columbia/Canada (2 aut.); Faculty of Pharmaceutical Sciences, University of British Columbia/Vancouver, British Columbia/Canada (3 aut.); Chilliwack General Hospital/Chilliwack, British Columbia/Canada (3 aut.); School of Population and Public Health, University of British Columbia/Vancouver, British Columbia/Canada (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Drugs & aging; ISSN 1170-229X; Nouvelle-Zélande; Da. 2009; Vol. 26; No. 9; Pp. 769-779; Bibl. 28 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Several studies have suggested that NSAID use may modify the risk of developing Parkinson's disease (PD). Objective: Our aim was to conduct a meta-analysis of observational studies evaluating NSAID use and the risk of PD. Methods: We systematically searched MEDLINE (1966-November 2008), EMBASE (1980-November 2008) and other databases. Data from 11 studies were included in the meta-analysis. We used the random effects model to calculate risk ratios (relative risks) and their corresponding 95% confidence intervals (CIs). Results: The pooled risk ratio of PD with NSAID use was 0.95 (95% CI 0.80, 1.12). The pooled risk ratio of PD with high-dose or long-duration NSAID use was 0.91 (95% CI 0.78, 1.05). The pooled risk ratio of PD for aspirin (acetylsalicylic acid) users was 1.08 (95% CI 0.93, 1.26). The pooled risk ratio of PD among ibuprofen users was 0.76 (95% CI 0.65, 0.89). The pooled risk ratio of PD in men using NSAIDs was 0.79 (95% CI 0.69, 0.92), and in women using NSAIDs, it was 0.72 (95% CI 0.45, 1.15). Conclusions: NSAIDs as a class do not seem to modify the risk of PD. However, ibuprofen may have a slight protective effect in lowering the risk of PD. Although the risk ratios of PD in male and female NSAID users were similar, the 95% CI for men was suggestive of a slight risk reduction.</EA>
<CC>002B02B05; 002B17G; 002B17A01</CC>
<FD>Antiinflammatoire non stéroïde; Facteur risque; Maladie de Parkinson; Revue systématique; Article synthèse; Métaanalyse; Personne âgée; Ibuprofène; Acide acétylsalicylique; Analgésique; Antipyrétique; Inhibiteur thromboagrégation; Risque relatif</FD>
<FG>Homme; Maladie dégénérative; Pathologie du système nerveux; Pathologie de l'encéphale; Syndrome extrapyramidal; Pathologie du   système nerveux central; Dérivé de l'acide arylpropionique; Inhibiteur enzyme; Prostaglandin-endoperoxide synthase; Oxidoreductases; Enzyme; Salicylés</FG>
<ED>Non steroidal antiinflammatory agent; Risk factor; Parkinson disease; Systematic review; Review; Metaanalysis; Elderly; Ibuprofen; Acetylsalicylic acid; Analgesic; Antipyretic; Antiplatelet agent; Relative risk</ED>
<EG>Human; Degenerative disease; Nervous system diseases; Cerebral disorder; Extrapyramidal syndrome; Central nervous system disease; Arylpropionic acid derivatives; Enzyme inhibitor; Prostaglandin-endoperoxide synthase; Oxidoreductases; Enzyme; Salicylates</EG>
<SD>Antiinflamatorio no esteroide; Factor riesgo; Parkinson enfermedad; Revisión sistemática; Artículo síntesis; Meta-análisis; Anciano; Ibuprofeno; Acetilsalicilico ácido; Analgésico; Antipirético; Inhibidor tromboagregación</SD>
<LO>INIST-26115.354000170024200040</LO>
<ID>09-0427296</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000511 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000511 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0427296
   |texte=   NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies

NSAID Use and the Risk of Parkinson's Disease: Systematic Review and Meta-Analysis of Observational Studies

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri